Both ADCs were more potent when tested in immunocompetent mouse models compared to immunodeficient hosts and CD8+ depletion using an anti-CD8 antibody significantly abrogated the efficacy of the ADCs in the CT26 model, suggesting a crucial role once again for effector T-lymphocytes in mediating anti-tumour activity. This evidence concerns the gene CD8A and neoplasm.